Friday, May 27, 2022 8:23:55 AM
"The NIH extended trial diverts our attention from the progress the Big Pharmas are making getting their mAbs into clinical trials. Another year, or less, of NIH trial testing could mean we lose our ability to maintain CMC compliance, if we can't financially reserve manufacturing capacity, maintain distribution agreements, or fulfill customer demand. It could mean that the FDA approves a Big Pharma mAb, and closes the EUA door.
Our fate is being wrested from us, with the successful completion of our internal Phase III trial, as the government attempts to commandeer our future...
Why would we need a larger patient population if a p value of 0.0003 and a Hazard Ratio of 2.96, can be obtained in a subset of that trial?"
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165875890&txt2find=commandeer
That was 8 months ago. Things have now changed in our favor. The NIH trial is completed and most likely confirmatory of our LIVE-AIR results. There are now more variants, and billions of dollars worth of Covid products the government has purchased are useless.
You seem equally assured of our failure now, as you always have been.
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM